



## Section 1.1: Support Requested (check all that apply)

- Benefits Investigation
- Appeals Support
- Co-Pay Assistance
- Prior Authorization Assistance
- Claims Assistance

### Patient Assistance Program

- Patient Assistance Program (PAP)

## Section 2.1: Patient Information

Patient Contact Information Attached

First Name: \_\_\_\_\_ Middle Initial: \_\_\_\_ Last Name: \_\_\_\_\_ SSN: \_\_\_\_\_ Gender:  Male  Female  
 Date of Birth: \_\_\_\_\_ Home Phone: \_\_\_\_\_ Cell Phone: \_\_\_\_\_ Alt Phone: \_\_\_\_\_ E-Mail: \_\_\_\_\_  
 Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_

## Section 2.2: Patient Insurance Information

Does the patient have insurance (third-party or private insurance)?  Yes  No

### Primary Insurance

(If copy of insurance card attached, check here )

Name: \_\_\_\_\_  
 Phone: \_\_\_\_\_  
 Insured Name: \_\_\_\_\_  
 Policy Number: \_\_\_\_\_  
 Employer: \_\_\_\_\_  
 Group Number: \_\_\_\_\_

### Secondary Insurance

(If copy of insurance card attached, check here )

Name: \_\_\_\_\_  
 Phone: \_\_\_\_\_  
 Insured Name: \_\_\_\_\_  
 Policy Number: \_\_\_\_\_  
 Employer: \_\_\_\_\_  
 Group Number: \_\_\_\_\_

## Section 3.1: Treatment Information/Prescription

**EYLEA® (afibercept) Injection**  Drug Allergies: \_\_\_\_\_  NKDA

**Dispense:** \_\_\_\_\_ Vial(s) **Refill:** \_\_\_\_\_ times Specialty pharmacy needed for dispensing?  Yes  No (MD office to supply)

(each vial is intended to deliver 0.05 mL of 40 mg/mL EYLEA) Preferred specialty pharmacy: \_\_\_\_\_

SIG:  Inject 2 mg (0.05 mL) every 4 weeks (monthly) for the first 3 injections followed by 2 mg (0.05 mL) once every 8 weeks

SIG:  Inject 2 mg (0.05 mL) every 4 weeks (monthly) for the first 5 injections followed by 2 mg (0.05 mL) once every 8 weeks

SIG:  Inject 2 mg (0.05 mL) every 4 weeks (monthly)

Ship to address (if different from office shown below): \_\_\_\_\_

## Section 4.1: Prescribing Physician Information

**Site of Service:**  Physician Office  Hospital Outpatient  Ambulatory Surgical Center Practice/Facility Name: \_\_\_\_\_

Physician Name: \_\_\_\_\_ E-Mail: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

Physician Specialty: \_\_\_\_\_ Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_

Physician's St Lic#: \_\_\_\_\_ Physician's DEA#: \_\_\_\_\_ Physician's PTAN: \_\_\_\_\_

Physician's Tax ID#: \_\_\_\_\_ Physician's National Provider Identifier (NPI): \_\_\_\_\_

## Section 4.2: Office Contact Information

Primary Office Contact: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ E-Mail: \_\_\_\_\_

## Section 4.3: Physician Certification

My signature below certifies that the person named on this form is my patient, the information provided on this application, to the best of my knowledge, is complete and accurate, and that EYLEA received in response to this application is only for the use of EYLEA for the patient named on this form. With regard to any patient eligible for patient assistance through the EYLEA4U® program, I acknowledge that this medication will not be offered for sale, trade, or barter and **EITHER** no claim for reimbursement of either EYLEA or related medical procedures and services will be submitted to Medicare, Medicaid, or any third-party payer **OR** I will provide appropriate denial and appeals documentation to support requests for patients who are deemed uninsured after a claim was submitted. I consent to Regeneron Pharmaceuticals, Inc. and its representatives and contractors contacting me by fax, phone, mail, or email to confirm receipt of EYLEA or provide additional information about EYLEA or the EYLEA4U program and that Regeneron Pharmaceuticals, Inc. may revise, change, or terminate any program services at any time without notice to me. I authorize Regeneron Pharmaceuticals, Inc. and its representatives and contractors to forward this prescription to a dispensing pharmacy on behalf of myself and my patient, and I appoint the EYLEA4U program solely to convey the prescription herein on my behalf to the pharmacy chosen by or for the above-named patient.

**Physician Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

## Section 5.1: Diagnosis

### Wet Age-related Macular Degeneration

Exudative age-related macular degeneration	Right eye	Left eye	Bilateral	Unspecified eye
With active choroidal neovascularization	<input type="checkbox"/> H35.3211	<input type="checkbox"/> H35.3221	<input type="checkbox"/> H35.3231	<input type="checkbox"/> H35.3291
With inactive choroidal neovascularization	<input type="checkbox"/> H35.3212	<input type="checkbox"/> H35.3222	<input type="checkbox"/> H35.3232	<input type="checkbox"/> H35.3292
With inactive scar	<input type="checkbox"/> H35.3213	<input type="checkbox"/> H35.3223	<input type="checkbox"/> H35.3233	<input type="checkbox"/> H35.3293
Stage unspecified	<input type="checkbox"/> H35.3210	<input type="checkbox"/> H35.3220	<input type="checkbox"/> H35.3230	<input type="checkbox"/> H35.3290

### Macular Edema following Retinal Vein Occlusion

Central retinal vein occlusion	Right eye	Left eye	Bilateral	Unspecified eye
With macular edema	<input type="checkbox"/> H34.8110	<input type="checkbox"/> H34.8120	<input type="checkbox"/> H34.8130	<input type="checkbox"/> H34.8190

Tributary (branch) retinal vein occlusion	Right eye	Left eye	Bilateral	Unspecified eye
With macular edema	<input type="checkbox"/> H34.8310	<input type="checkbox"/> H34.8320	<input type="checkbox"/> H34.8330	<input type="checkbox"/> H34.8390

### Diabetic Macular Edema (DME) | Diabetic Retinopathy (DR) in Patients with DME

Diabetes mellitus due to underlying condition with...	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E08.3211	<input type="checkbox"/> E08.3212	<input type="checkbox"/> E08.3213	<input type="checkbox"/> E08.3219
Moderate nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E08.3311	<input type="checkbox"/> E08.3312	<input type="checkbox"/> E08.3313	<input type="checkbox"/> E08.3319
Severe nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E08.3411	<input type="checkbox"/> E08.3412	<input type="checkbox"/> E08.3413	<input type="checkbox"/> E08.3419
Proliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E08.3511	<input type="checkbox"/> E08.3512	<input type="checkbox"/> E08.3513	<input type="checkbox"/> E08.3519

Drug or chemical induced diabetes mellitus with...	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E09.3211	<input type="checkbox"/> E09.3212	<input type="checkbox"/> E09.3213	<input type="checkbox"/> E09.3219
Moderate nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E09.3311	<input type="checkbox"/> E09.3312	<input type="checkbox"/> E09.3313	<input type="checkbox"/> E09.3319
Severe nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E09.3411	<input type="checkbox"/> E09.3412	<input type="checkbox"/> E09.3413	<input type="checkbox"/> E09.3419
Proliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E09.3511	<input type="checkbox"/> E09.3512	<input type="checkbox"/> E09.3513	<input type="checkbox"/> E09.3519

Type 1 diabetes mellitus with...	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E10.3211	<input type="checkbox"/> E10.3212	<input type="checkbox"/> E10.3213	<input type="checkbox"/> E10.3219
Moderate nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E10.3311	<input type="checkbox"/> E10.3312	<input type="checkbox"/> E10.3313	<input type="checkbox"/> E10.3319
Severe nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E10.3411	<input type="checkbox"/> E10.3412	<input type="checkbox"/> E10.3413	<input type="checkbox"/> E10.3419
Proliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E10.3511	<input type="checkbox"/> E10.3512	<input type="checkbox"/> E10.3513	<input type="checkbox"/> E10.3519

Type 2 diabetes mellitus with...	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E11.3211	<input type="checkbox"/> E11.3212	<input type="checkbox"/> E11.3213	<input type="checkbox"/> E11.3219
Moderate nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E11.3311	<input type="checkbox"/> E11.3312	<input type="checkbox"/> E11.3313	<input type="checkbox"/> E11.3319
Severe nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E11.3411	<input type="checkbox"/> E11.3412	<input type="checkbox"/> E11.3413	<input type="checkbox"/> E11.3419
Proliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E11.3511	<input type="checkbox"/> E11.3512	<input type="checkbox"/> E11.3513	<input type="checkbox"/> E11.3519

Other specified diabetes mellitus with...	Right eye	Left eye	Bilateral	Unspecified eye
Mild nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E13.3211	<input type="checkbox"/> E13.3212	<input type="checkbox"/> E13.3213	<input type="checkbox"/> E13.3219
Moderate nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E13.3311	<input type="checkbox"/> E13.3312	<input type="checkbox"/> E13.3313	<input type="checkbox"/> E13.3319
Severe nonproliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E13.3411	<input type="checkbox"/> E13.3412	<input type="checkbox"/> E13.3413	<input type="checkbox"/> E13.3419
Proliferative diabetic retinopathy with macular edema	<input type="checkbox"/> E13.3511	<input type="checkbox"/> E13.3512	<input type="checkbox"/> E13.3513	<input type="checkbox"/> E13.3519

Other (only available for PAP) \_\_\_\_\_

Visual Acuity: Right Eye: \_\_\_\_\_ / \_\_\_\_\_  
Left Eye: \_\_\_\_\_ / \_\_\_\_\_

Has patient started treatment?  Yes  No  
Anticipated date of treatment: \_\_\_\_\_

**Patient Name**

First Name: \_\_\_\_\_ Middle Initial: \_\_\_\_\_ Last Name: \_\_\_\_\_

Preferred Language:  English  Spanish  Other: \_\_\_\_\_

**Section 6.1: Authorization to Disclose/Use Health Information**

I authorize my health care providers, my health insurer, health plan or programs that provide me health care benefits (together, "Health Insurers") and any specialty pharmacies to disclose to Regeneron Pharmaceuticals, Inc. and its representatives and contractors (together, "Regeneron") the information related to my treatment with EYLEA® (aflibercept) Injection (together, "My Information"). My health care providers, Health Insurers, specialty pharmacy and Regeneron may use and disclose My Information for the following purposes:

- to determine if I am eligible to participate in Regeneron’s reimbursement assistance program, patient assistance program and other support programs (together, "EYLEA4U® Programs");
- for the operation and administration of the EYLEA4U Programs;
- to investigate my health insurance coverage benefits;
- to obtain prior authorization for reimbursement;
- to assist with appeals of denied claims for reimbursement; and
- to refer me to, or to determine my eligibility for, other programs, foundations or alternate sources of funding or coverage that may be available to provide assistance to me with the costs of my medications.

I understand and agree that my health care providers, Health Insurers and specialty pharmacy may receive remuneration from Regeneron in exchange for disclosing My Information to Regeneron and/or for providing me with support services in connection with the EYLEA4U Programs. I understand that, once My Information has been disclosed to Regeneron, federal privacy laws may no longer protect it. However, Regeneron agrees to protect My Information by using and disclosing it only for the purposes authorized in this Authorization or as required by law.

I understand that if I refuse to sign this Authorization, I will not be able to participate in the EYLEA4U Programs, but it will not affect my eligibility to obtain medical treatment, my ability to seek payment for this treatment or affect my insurance enrollment or eligibility for insurance coverage.

Further, I understand that I may withdraw (take back) this Authorization at any time by mailing or faxing a written request to Regeneron at P.O. Box 220578, Charlotte, NC 28222-0578; Fax: (888) 335-3264. Withdrawal of this Authorization will end further uses and disclosures of My Information by the parties identified in this Authorization except to the extent those uses and disclosures have been made in reliance upon this Authorization.

This Authorization expires 18 months from the date support is last provided under any EYLEA4U Program unless I withdraw it earlier. For residents of California, this authorization expires 18 months from the date indicated below unless I withdraw it earlier. I understand that I will receive a copy of this Authorization.

 **Patient Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Section 6.2: Financial Information** (must be completed for patient assistance requests)

**Total Household Income** (including salary/wages; Social Security income; disability income; any other income):\*

- \$0 to \$100,000
- Greater than \$100,000

\*Supporting documentation will be required.

**Please complete this application and submit by fax to 1-888-335-3264 or retain completed and patient-signed form on file at your office if submission is entered via the e-Portal.**

## Patient Name

First Name: \_\_\_\_\_ Middle Initial: \_\_\_\_\_ Last Name: \_\_\_\_\_  
Preferred Language:  English  Spanish  Other: \_\_\_\_\_

### Section 6.3: Patient Certification

By signing below, I am enrolling in the EYLEA4U® Programs, and authorize Regeneron to provide me with the EYLEA4U Programs. I verify that the information on this application and other supporting documentation is complete and accurate. I also verify that unless I have identified otherwise in this application, I have no other coverage for prescription medications, including Medicaid, Medicare or any public or private assistance programs, or any other form of insurance.

I also agree that Regeneron may verify my eligibility for the EYLEA4U Programs, and I understand that such verification may include contacting me or my health care provider for additional information and/or reviewing additional financial, insurance, and/or medical information. I authorize Regeneron to use my Social Security number and/or additional demographic information to access reports on my individual credit history from consumer reporting agencies. I understand that upon request, Regeneron will tell me whether an individual consumer report was requested and the name and address of the agency that furnished it. I further understand and authorize Regeneron to use any consumer reports about me and information collected from me, along with other information they obtain from public and other sources to estimate my income in conjunction with the patient assistance program eligibility determination process, if applicable.

I authorize Regeneron to contact me by mail, telephone, or email, with information about the EYLEA4U Programs, FDA-approved indications of EYLEA® (aflibercept) Injection, related disease state information and products, promotions, services and research studies, and to ask my opinion about such information and topics, including market research and disease-related surveys. I further authorize Regeneron to de-identify my health information and use it in performing research, education, business analytics, marketing studies or for other commercial purposes. I understand that members of Regeneron may share identifiable health information with one another in order to de-identify it for these purposes and as needed to perform the EYLEA4U Programs or to send the communications listed above (the "Communications"). I understand and agree that Regeneron may use my health information for these purposes and may share my health information with my doctors, specialty pharmacies, and insurers.

In connection with administering the EYLEA4U Programs, I understand that Regeneron may contact me or my health care provider directly to confirm receipt of medications or to provide other information related to the EYLEA4U Programs. I also understand that Regeneron may revise, change or terminate the EYLEA4U Programs at any time.

I understand that I do not have to enroll in the EYLEA4U Programs or receive the Communications, and that I can still receive EYLEA as prescribed by my physician. I may opt out of receiving Communications, individual programs offered by the EYLEA4U Programs or opt out of the EYLEA4U Programs entirely at any time by mailing or faxing a written request to Regeneron at P.O. Box 220578, Charlotte, NC 28222-0578; Fax: (888) 335-3264.

 **Patient Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

### Section 6.4: Physician Patient Signature Certification

(must be signed by the physician when Enrollment Form submissions are entered via the e-Portal)

My signature below certifies the following: (i) that the person named on this Enrollment Form is my patient, (ii) that I have obtained his/her written authorization and certification under Sections 6.1 and 6.3 of this form, (iii) that to the best of my knowledge the information, if applicable, under Section 6.2 of this form is accurate and complete, (iv) that I will retain in my files the complete patient-executed Enrollment Form, and (v) that upon request, I will promptly provide a copy of this patient-executed Enrollment Form on file to EYLEA4U.

 **Physician Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**Please complete this application and submit by fax to 1-888-335-3264 or retain completed and patient-signed form on file at your office if submission is entered via the e-Portal.**

EYLEA and EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

**REGENERON**